Clearside Biomedical’s Leadership to Discuss Revolutionary Eye Therapy Delivery at Oppenheimer Conference
Alpharetta, GA, February 4, 2025 – Clearside Biomedical, Inc., a trailblazing biopharmaceutical company, is set to make waves in the medical industry with their innovative approach to delivering therapies to the back of the eye through the suprachoroidal space (SCS®). On Tuesday, February 11, 2025, at 9:20 a.m. ET, George Lasezkay, PharmD, JD, President and CEO, and Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development, will share insights about this groundbreaking technology during a Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference.
About Clearside Biomedical and the SCS® Technology
Clearside Biomedical is a leading biopharmaceutical company dedicated to transforming the delivery of therapies to the back of the eye, offering hope for patients suffering from various retinal diseases. The company’s proprietary SCS® technology enables direct access to the suprachoroidal space, which is a unique and largely unexplored area between the choroid and the sclera. This non-invasive approach allows for targeted drug delivery, bypassing the challenges of traditional methods like systemic administration or intravitreal injections.
Impact on Patients
For patients, the SCS® technology offers several advantages. By delivering treatments directly to the affected area, the risk of systemic side effects is significantly reduced, as the drug does not enter the bloodstream. Additionally, the procedure is less invasive than intravitreal injections, which can be a source of anxiety for some patients. The SCS® approach can potentially lead to better treatment outcomes, as the drug remains in the target area for a more extended period, ensuring consistent therapeutic effect.
Impact on the World
The potential impact of Clearside Biomedical’s SCS® technology on the world goes beyond individual patients. By addressing the challenges of delivering therapies to the back of the eye, the company is paving the way for a new era in ophthalmology. This innovative approach has the potential to revolutionize the treatment landscape for various retinal diseases, including macular edema, diabetic retinopathy, and age-related macular degeneration. Furthermore, the SCS® technology may enable the development of new therapies that were previously considered impractical due to the challenges of delivering them to the back of the eye.
Fireside Chat at Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
During the Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference, George Lasezkay and Victor Chong will discuss the latest advancements in Clearside Biomedical’s SCS® technology and its potential impact on the medical industry. They will also share insights into the company’s pipeline, including its lead product, XIPERE™ (triamcinolone acetonide injectable suspension) for the treatment of diabetic macular edema, which is currently under review by the U.S. Food and Drug Administration (FDA).
Conclusion
Clearside Biomedical’s groundbreaking SCS® technology represents a significant step forward in the delivery of therapies to the back of the eye. With its potential to reduce systemic side effects, offer less invasive procedures, and improve treatment outcomes, this innovative approach is poised to revolutionize the treatment landscape for various retinal diseases. Join George Lasezkay and Victor Chong on February 11, 2025, at 9:20 a.m. ET, for an enlightening Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference to learn more about this exciting development in the medical industry.
- Clearside Biomedical is a pioneering biopharmaceutical company focused on transforming the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®).
- The SCS® technology offers several advantages for patients, including reduced systemic side effects, less invasive procedures, and better treatment outcomes.
- The potential impact of Clearside Biomedical’s SCS® technology extends beyond individual patients, paving the way for a new era in ophthalmology and enabling the development of new therapies.
- George Lasezkay and Victor Chong will share insights into Clearside Biomedical’s pipeline and the latest advancements in the SCS® technology during a Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference on February 11, 2025.
